GlassScriptPhysician profile
Dustin Marks
NPI 1497379184
$5,624.68
in general payments reported to CMS, 2019-2025
27 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.50 · 2022: $1,271 · 2023: $328 · 2024: $1,392 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,418 · Travel and Lodging: $585 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,417.76 |
| Travel and Lodging | $585.01 |
| Education | $258.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,895.89 | 2021-2025 | |
| Allergan, INC. | $642.40 | 2022 | |
| Janssen Biotech, INC. | $498.74 | 2024-2025 | Tremfya |
| Revance Therapeutics, INC. | $316.13 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $255.13 | 2025 | Aklief, Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $239.53 | 2022-2023 | Sotyktu |
| Merz North America, INC. | $179.17 | 2024 | |
| Incyte Corporation | $157.49 | 2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $154.05 | 2022-2025 | Libtayo |
| Pfizer INC. | $139.80 | 2024-2025 | |
| Almirall LLC | $137.81 | 2024-2025 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.62 | 2023 | |
| Novartis Pharmaceuticals Corporation | $111.27 | 2025 | |
| Ucb, INC. | $105.28 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $94.22 | 2024-2025 | Ebglyss, Taltz, Olumiant |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Mayne Pharma Commercial LLC | $73.54 | 2025 | |
| Genzyme Corporation | $67.84 | 2025 | |
| Janssen Scientific Affairs, LLC | $60.00 | 2024 | Tremfya |
| Amgen INC. | $53.78 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $48.66 | 2025 | |
| Cipher Pharmaceuticals US LLC | $48.63 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $38.05 | 2025 | Ycanth |
| Journey Medical Corporation | $27.32 | 2025 | |
| Organon LLC | $26.74 | 2025 | |
| Leo Pharma INC. | $26.12 | 2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.48 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.